| Literature DB >> 36163473 |
Juan Hernando Del Portillo-Navarrete1,2,3, Alejandro Pizano4, Jhonattan Benavides5, Andres M Palacio5, Karen Moreno-Medina6, Jaime Cabrales4,7,5, Darío Echeverri4,7,5.
Abstract
Pericardial effusions requiring pericardiocentesis have multiple causes that vary among geographical regions and health contexts. This procedure can be performed for diagnostic or therapeutic indications. The purpose of this study was to identify the principal causes of pericardial effusions and indications for pericardiocentesis, exploring differences among groups. This was a retrospective case series of patients who underwent pericardiocentesis for pericardial effusion in a single center in Latin America. Demographic, clinical, echocardiographic, and procedural variables were recorded and analyzed. The primary outcome was to determine the causes of pericardial effusions in these patients and the indication (diagnostic, therapeutic, or both). The results are presented in two groups (inflammatory and noninflammatory) according to the cause of the pericardial effusion. One hundred sixteen patients with pericardial effusion underwent pericardiocentesis. The median age was 58 years (IQR 46.2-70.7), and 50% were male. In the noninflammatory pericardial effusion group, there were 61 cases (53%), among which neoplastic pericardial effusion was the most frequent cause (n = 25, 40.9%). In the inflammatory group, there were 55 cases (47%), and the main cause was postpericardiectomy syndrome after cardiac surgery (n = 31, 56.4%). In conclusion, the principal indication for pericardiocentesis was therapeutic (n = 66, 56.8%). Large pericardial effusion without hemodynamic effect of cardiac tamponade was significantly more frequent in the inflammatory group (p = 0.03). The principal cause of pericardial effusion in patients who underwent pericardiocentesis was postpericardiectomy syndrome after cardiac surgery, followed by neoplastic pericardial effusion. Pericardiocentesis is mainly a therapeutic procedure.Entities:
Mesh:
Year: 2022 PMID: 36163473 PMCID: PMC9512803 DOI: 10.1038/s41598-022-19339-6
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.996
Baseline clinical characteristics of the patients.
| Pericardial effusion type | ||
|---|---|---|
| Inflammatory (n = 55) | Non-inflammatory (n = 61) | |
| Male sex, no. (%) | 28 (50.9) | 29 (49.2) |
| Age years, median (IQR) | 55 (40–69) | 61 (49–71) |
| Weight kg, median (IQR) | 65 (56.8–73.4) | 63.7 (56–73) |
| Height m, (IQR) | 1.64 (1.55–1.70) | 1.60 (1.53–1.70) |
| Asymptomatic (%) | 3 (5.5) | 3 (4.9) |
| Dyspnea | 23 (41.8) | 27 (44.3) |
| Hypotension | 12 (21.8) | 20 (32.8) |
| Tachycardia | 2 (3.6) | 4 (6.6) |
| Pericardial chest pain | 21 (38.2) | 10 (16.4) |
| Cardiac arrest, shock, syncope | 2 (3.6) | 3 (4.9) |
| I | 16 (29.1) | 14 (23.0) |
| II | 26 (47.3) | 23 (37.7) |
| III | 12 (21.8) | 18 (29.5) |
| IV | 1 (1.8) | 6 (9.8) |
| Large pericardial effusion without hemodynamic effect* | 15 (27.3) | 7 (11.5) |
| Clinical manifestations cardiac tamponade with or without aborted cardiac arrest | 13 (23.6) | 22 (36.1) |
| Echocardiographic signs of cardiac tamponade without clinical manifestations | 27 (49.1) | 32 (52.5) |
| Anemia | 37 (67.3) | 38 (62.3) |
| Renal replacement therapy | 1 (1.8) | 4 (6.6) |
| Previous cardiac procedures | 36 (65.5) | 29 (47.5) |
| Use of anticoagulants | 20 (36.4) | 22 (36.1) |
| Unfractionated heparin | 1 (1.8) | 9 (14.8) |
| Low-molecular-weight heparin | 2 (3.6) | 6 (9.8) |
| Warfarine | 15 (27.3) | 6 (9.8) |
| Rivaroxaban | 2 (3.6) | 1 (1.6) |
*Large pericardial effusion without hemodynamic effect was significantly more frequent in the inflammatory group (p = 0.03).
Specific inflammatory and noninflammatory causes of pericardial effusion.
| n (%) | |
|---|---|
| Late pericardial effusion postcardiac surgery* | 31 (56.4) |
| Infectious | 6 (10.9) |
| Autoimmune | 6 (10.9) |
| Idiopathic pericarditis | 8 (14.5) |
| Immunosuppressive medications | 2 (3.6) |
| Idiopathic pericardial effusion | 2 (3.6) |
| Neoplastic | 25 (40.9) |
| Early pericardial effusion postcardiac surgery+ | 13 (21.3) |
| Postcoronary interventions | 11 (18.0) |
| Chronic renal failure | 5 (8.2) |
| Traumatic | 4 (6.6) |
| Post permanent or transitory pacemaker implantation | 2 (3.2) |
| Anticoagulation therapy | 1 (1.6) |
*Late pericardial effusion postcardiac surgery was defined as pericardial effusion that presented ten days after surgery related to postpericardiectomy syndrome. +Early pericardial effusion postcardiac surgery was defined as pericardial effusion that presented during the first ten days after surgery.
Figure 1Central illustration. (a) Fluoroscopy guidance pericardiocentesis with the puncturing needle crossing the pericardium (red line). (b) Guidewire around the heart shadow (blue line) and pericardium space that contains PE between the pericardium and heart shadow (yellow arrow). (c) Percentages of specific causes in the inflammatory and noninflammatory groups. Percentage of diagnostic, therapeutic or both indications for pericardiocentesis in the inflammatory and noninflammatory groups. *There were no cases of only diagnostic indication for pericardiocentesis in the non-inflammatory group. Percentage of pericardial effusion composition in the groups and pericardial effusion composition examples.
Principal demographic and clinical characteristics of series of pericardiocentesis.
| Region ( | Cases, n | Male sex, % | Age years, mean ± SD | Principal causes of pericardial effusionϕ | Pericardial effusions compositions, (%) |
|---|---|---|---|---|---|
| Spain/Europe ( | 126 | 52 | 56 ± 17 | Idiopathic pericarditis | Not described |
| Iatrogenic effusion Neoplastic | |||||
| USA/North America ( | 441 | 53 | 54 ± 14 | Postsurgical | Hemopericardium, (51) |
| Neoplastic | Hydropericardium, (44) | ||||
| Cardiac perforation from invasive procedure | Other, (5) | ||||
| China/Asia ( | 140 | 51 | 15–71+ | Neoplastic Tuberculous pericarditis | Hemopericardium, (90) |
| Iatrogenic | Hydropericardium, (6) | ||||
| Other, (4) | |||||
| Singapore/Asia ( | 149 | 54 | 64 ± 15 | Neoplastic | Hemopericardium, (77) |
| Postsurgical | Hydropericardium, (23) | ||||
| Effusion associated with pneumonia | |||||
| Colombia/South America ( | 116 | 50 | 46–71+ | Post cardiac surgery | Hemopericardium, (52) |
| Neoplastic | Hydropericardium, (42) | ||||
| Post coronary interventions | Pyopericardium, (6,0) |
*Last period of the series between 1993–2000. +Age reported in interquartile range (IQR). ϕThe three principal causes reported in each case series.